Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acyclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP known ✓ | P00491 | 10/20 | 0.97 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | HBB | P68871 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | VCP | P55072 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acyclovir SCHEMBL29165535 | 0.99 | PNP (0.95) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3664893 | 0.99 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL2269160 | 0.99 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3175 | 0.99 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL6239258 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16060281 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL19031784 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL29531632 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL1690304 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL40724 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462678-B | Acyclovir nanocrystalline and preparation method thereof | 成都医学院 | 2024-08-20 | — | — | CN | claimed |
| CN-116462678-A | Acyclovir nanocrystalline and preparation method thereof | 成都医学院 | 2023-07-21 | — | — | CN | claimed |
| US-20160002240-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2016-01-07 | — | — | US | claimed |
| WO-2014145464-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-09-18 | — | — | WO | claimed |
| CN-112494827-B | Therapeutic device for herpes zoster | 汇云数据应用(福州)有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114621227-A | Valaciclovir hydrochloride, preparation and preparation method thereof | 海南久常制药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114533739-A | Application of nucleoside analogue in preparing medicine for preventing or treating gastrointestinal tract diseases | 兰州大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-111763980-B | Antibacterial and antiviral stainless steel and preparation method thereof | 南京同曦同康抗菌材料科技有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113274356-A | Valaciclovir hydrochloride granules and preparation method thereof | 丽珠集团丽珠制药厂 | 2021-08-20 | — | — | CN | disclosed |
| CN-111763980-A | Antibacterial and antiviral stainless steel and preparation method thereof | 南京同曦同康抗菌材料科技有限公司 | 2020-10-13 | — | — | CN | disclosed |
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| US-20160002240-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2016-01-07 | — | — | US | disclosed |
| WO-2014145464-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002240-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | ADAR, SLC28A1, SLC28A2 | PNP 6/4885EDNRA 3594/4885HTR2A 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.